U-73122 NEW
| Price | $33 | $52 | $77 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: U-73122 | CAS No.: 112648-68-7 |
| Purity: 96.73% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | U-73122 |
| Description | U-73122 (U73122) , an effective PLC inhibitor, reduces agonist-induced Ca2+ increases in platelets and PMN. |
| Cell Research | U-73122 is dissolved in DMSO. Agonist-induced production of IP3 in PMN is measured by use of the competitive radiobinding assy. PMN (2 x 106-107) in 0.2 mL of phosphate-buffered saline, pH 7.4 [NaC1 (138 mM), Na2HPO4 (8.1 mM), KH2PO4 (1.5 mM), KCI (2.7 mM), CaCl2 (1.0 mM), MgC12 (1.0 mM) and glucose (0.1%, w/v)] are incubated in conical polypropylene tubes at 37°C in a shaking water bath. U-73122 or U-73343 is added (in 1 μL of DMSO) 3 min before the addition of agonist, FMLP (0.1 μM) plus cytochalasin B (5 μg/mL). FMLP and cytochalasin B are added in 1 μL each of DMSO and ethanol, respectively. Appropriate vehicle controls are included in each experiment. PMN incubation mixtures are quenched with the addition of 0.07 mL of ice-cold TCA (20%, w/v) and a portion (0.2 mL) of the TCA extract is processed for the measurement of IP3 by competitive radiobinding as described above for platelets. |
| Kinase Assay | PMNs (4×107/4 mL) are incubated with U-73122 according to protocols. The reactions are stopped with cold calcium-free PBS. The cells are centrifuged at 750 × g (4°C) and resuspended in 1 mL of Triton X-100-free extraction buffer (50 mM Tris, pH 7.5, 50 mM fimercaptoethanol, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride and 4 μg/mL of leupeptin, soybean trypsin inhibitor and aprotinin), and then sonicated for 10- and 5-sec consecutive bursts at 20% output. The lysates are centrifuged at 240 × g (4°C) for 20 mm in a TL-100 ultracentrifuge with the supernatant designated as the cytosol fraction. The pellet is resuspended in 1% Triton-containing extraction buffer, sonicated, shaken for 30 mm at 4°C and centrifuged (240 × g for 20 mm at 4°C). The supernatant constitutes the extractable particulate fraction, and the pellet is sonicated in extraction buffer with Triton and constituted the nonextractable particulate fraction. |
| In vitro | At a concentration of 0.1 mg/ml, U73122 inhibits the accumulation of 74% of lymphocytes and 65% of macrophages induced by carrageenan in the subcutaneous cavity of dogs. When administered at 30 mg/kg intraperitoneally (i.p.), U73122 blocks 65% and 80% of carrageenan-induced paw edema in rats 1 hour and 3 hours post-treatment, respectively. Furthermore, it completely inhibits the infiltration of macrophages and lymphocytes, as well as 80% of prostaglandin E2 production, in a mouse model of peritonitis triggered by lipopolysaccharides. U73122 also suppresses the swelling of mouse ears induced by 12-O-tetradecanoylphorbol-13-acetate. |
| In vivo | U-73122 inhibits the production of thromboxane B induced by collagen, where collagen induces this effect by inhibiting receptor-coupled arachidonic acid transfer. U-73122 also suppresses the aggregation of human polymorphonuclear neutrophils and the associated production of IP3 and diacylglycerol induced by FMLP. It notably inhibits the aggregation of human platelets induced by various agonists, including thrombin, collagen, ADP, and arachidonic acid (IC50 of 1-5 μM). Thrombin or U-46619 induces the production of IP3 and a subsequent rapid increase in intracellular Ca2+ by inhibiting the hydrolysis of platelet-soluble components catalyzed phosphatidylinositol [3H]mannose and phosphatidylinositol [3H]bisphosphate 4,5-diphosphate (Ki: 9/40 μM), which is inhibited by 10 μM of U-73122. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5.63 mg/mL (12.11 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.25 mg/mL (2.69 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| Keywords | inhibit | Phospholipase | Inhibitor | U-73122 | Ferroptosis | Lipoxygenase | U 73122 | LOX |
| Inhibitors Related | Neomycin sulfate | TBHQ | Acetylcysteine | Butylated hydroxytoluene | α-Vitamin E | Sorafenib | Curcumin | Artemisinin | L-Cystine | L-Glutamic acid monosodium salt | Coenzyme Q10 | 5-Aminosalicylic Acid |
| Related Compound Libraries | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Preclinical Compound Library | Wnt/Hedgehog/Notch Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY